Aktie A2H78Z ZHEJIANG STARRY PHARMACEUTICAL CO.,LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Zhejiang Starry Pharmaceutical Co.,Ltd.

Aktien

A2H78Z

CNE1000026N8

603520

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 10.05.2024 		% 5 Tage % 1. Jan.
12,64 CNY -2,62 % Intraday Chart für Zhejiang Starry Pharmaceutical Co.,Ltd. +0,56 % -10,23 %
29.04. Zhejiang Starry Pharmaceutical Co.,Ltd. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
29.04. Zhejiang Starry Pharmaceutical Co.,Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Hu Jinsheng agreed to acquire 36% stake in Xianju Juhe Financial Services Co., Ltd. from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 19.8 million.
Shanghai Ddsome Laboratories Co., Ltd announced that it has received funding from Zhejiang Huahai Pharmaceutical Co., Ltd., Zhejiang Starry Pharmaceutical Co.,Ltd.
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Shanghai Ddsome Laboratories Co., Ltd announced that it expects to receive CNY 28 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.
Starry Pharma’s Generic X-Ray Contrast Agent Gets Marketing Approval
Zhejiang Starry Pharma’s CFO Resigns
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Zhejiang Starry Pharmaceutical Co.,Ltd. agreed to acquire 18% Shanghai Starry Pharmaceutical Co., Ltd. from Jiaxing Juli Stellite Equity Investment Partnership.
Zhejiang Starry Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 2.05 billion in funding
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Zhejiang Starry Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Zhejiang Zhumei Import and Export Group Co., Ltd agreed to acquire Zhejiang Xianju Thermal Power Co., Ltd from Zhejiang Starry Pharmaceutical Co.,Ltd. for CNY 35 million.
Zhejiang Starry Pharmaceutical Co.,Ltd.(SHSE:603520) dropped from Shanghai Stock Exchange Health Care Sector Index
Zhejiang Hisyn Pharmaceutical Co., Ltd. announced that it has received CNY 110.2637 million in funding from Zhejiang Starry Pharmaceutical Co.,Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2H78Z Aktie
  4. Nachrichten Zhejiang Starry Pharmaceutical Co.,Ltd.
  5. Andere Sprachen